| abstract |
The present invention relates to oral solid dosage forms that contain a very low dose of estradiol. Dosage forms are formulated in such a way as to avoid degradation of estradiol and minimize the content of polyvinylpyrrolidone, while at the same time achieving similar rapid dissolution of estradiol. Dosage forms are useful in the prevention or treatment of physical conditions in women caused by insufficient endogenous levels of estradiol. |